Today's Trend
AnaptysBio, Inc. (ANAB) — The stock is down today after a mix of recent developments: a sharp, short‑lived rally on heavy volume and analyst previews that caution about an upcoming quarterly miss have been overshadowed by a legal setback in AnaptysBio’s licensing dispute with GSK/TESARO. Trading volume is elevated versus average and the shares remain well above their 50‑ and 200‑day moving averages, but near recent highs, making the legal and earnings headlines more influential for near‑term direction.
- AnaptysBio jumped ~14.8% in the prior session on higher‑than‑average volume, indicating strong short‑term buying interest and increased investor attention; this surge likely contributed to elevated intraday volatility. ANAB Surges 14.8%
- Zacks published a Q1 preview noting AnaptysBio “may report negative earnings,” flagging that the company lacks the typical setup that leads to an earnings beat; this is a pre‑release expectation rather than confirmed results, so it creates caution but not a realized hit. ANAB May Report Negative Earnings
- The Delaware Chancery Court granted TESARO/GSK’s motion to dismiss AnaptysBio’s anticipatory‑breach counterclaim in their dostarlimab licence dispute, a partial legal loss that increases near‑term litigation risk and uncertainty around the commercial relationship; investors often view such rulings as a negative catalyst for biotech partners. GSK unit wins partial dismissal in dostarlimab licence dispute
What investors should watch next: the company’s upcoming Q1 report and any legal filings/appeals in the TESARO dispute. Those two items — confirmed quarterly results vs. expectations, and how the licence litigation develops — are the most likely near‑term drivers of ANAB’s share price.